Skip to main content
. 2017 Jan 28;8(8):14017–14028. doi: 10.18632/oncotarget.14876

Figure 5. CUDC-907 therapy in xenograft model of GCB and ABC DLBCL.

Figure 5

(A) Human SUDHL-6 and TMD-8 DLBCL cells were established as s.c. tumors in NOD/SCID mice and treated orally with vehicle (n = 8) or CUDC-907 at 25 (n = 8), 50 (n = 8) and 100 (n = 8) mg/kg, 5 times weekly. CUDC-907 inhibits tumor growth in a dose-dependent manner when compared with the control group. Tumor volume was measured 3 times per week. Differences between groups were calculated with the Student's t test. **p < 0.005; ***p = 0.0001; ****p < 0.00001. (B) Variations of body weight over time in SUDHL-6 and TMD-8 xenografts treated with CUDC-907 at 25, 50 and 50 mg/kg. (C) In vivo effects of CUDC-907 on pS6, c-Myc, MyD88, IRF4, PARP and acetyl histone H3 levels in SUDHL-6 and TMD-8 xenografts after 24 hours from the last drug administration. Proteins were extracted from tumor tissues and analyzed by western immunoblotting to assess in vivo inhibition of indicated targets. (D) Scatterplots summarizing changes in expression levels of pS6, c-Myc, MyD88 and IRF4, expressed as ratios of pixel densities between actin and protein of interest. Densitometry was performed by using the ImageJ software. Differences between groups were calculated with the Wilcoxon Rank test. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.